76 Everolimus for the Prevention of Microvasculopathy in Biopsy: Final Results from Re-Evaluation of the RAD B253 Trial

Purpose We recently presented preliminary data on the preventive effects of everolimus (EVE) on biopsy-proven microvasculopathy (MVP) after heart transplantation (HTx). Here we show the final analysis from re-evaluation of the European cohort of the RAD B253 Trial (EVE 3 mg or 1.5 mg vs. azathioprine [AZA] in primary HTx pts). Methods and Materials We studied 135 pts, mean age 56 yrs, and 567 biopsies harvested 1 wk (n=125), 4 wks (n=131), 3 months (n=128), 1 yr (n=101) and 2 yrs (n=82) after HTx. Acute cellular rejection (ACR; ISHLT) and both endothelial disease (endothelial cell layer at least as thick as its cell cores) and MVP (ratio of luminal radius to media thickness Conclusions Everolimus suppresses MVP in biopsy early after HTx and seems to have preventive effects on endothelial disease, also. Its effects beyond the first post-transplant yr deserve further study.